SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Inozyme Pharma, Inc. (INZY) .
Criteria proven by this page:
- VALUE (50/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Analyst consensus target $4.00 (+0% upside) — modest upside expected.
Overall SharesGrow Score: 32/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
50/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — INZY
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.62
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$4.00 (+0%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.46 |
$0.00 |
$-6.96M |
- |
| 2019 |
$-1.23 |
$0.00 |
$-18.62M |
- |
| 2020 |
$-2.39 |
$0.00 |
$-55.84M |
- |
| 2021 |
$-2.39 |
$0.00 |
$-56.41M |
- |
| 2022 |
$-1.73 |
$0.00 |
$-65.45M |
- |
| 2023 |
$-1.37 |
$0.00 |
$-71.17M |
- |
| 2024 |
$-1.62 |
$0.00 |
$-102.02M |
- |
